BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
1. 
The  applicant  Glaxo  Group  Ltd  and  submitted  on  6  April  2001  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
PritorPlus, through the centralised procedure. After agreement by the CPMP on 23 January 2001, this 
medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 
of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Prof. Silvio Garattini 
Co-Rapporteur:   Prof. Rolf Bass 
Scientific Advice: 
The applicant did not seek scientific advice at the CPMP. 
Licensing status: 
A  new  application  was  filed  in  the  following  countries:  Republic  South  Africa  and  Canada.  The 
product was licensed in the U.S.A. at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 24 April 2001. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 3 July 2001 
(Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all CPMP members 
on 6 July 2001 (Annex 2) 
During the meeting on 26 July 2001 the CPMP agreed on the consolidated List of Questions to 
be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 26 
July 2001 (Annex 3). 
The company submitted the responses to the CPMP consolidated List of Questions on 8 October 
2001 
The  Rapporteur  and  Co-Rapporteur  circulated  the  response  Assessment  Report  on  the 
company’s  responses  to  the  List  of  Questions  to  all  CPMP  members  on  14  November  2001 
(Annex 4). 
During  the  CPMP  meeting  on  13  December  2001,  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP (Annex 5). 
The company submitted the responses to the List of Outstanding Issues on 20 December 2001. 
During the meeting on 15-17 January 2002 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to PritorPlus on 17 January 2002. 
•  The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 22 April 2002. 
1/1 
EMEA 2004 
 
 
 
